# A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

> **NCT03921411** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 20 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** Nemolizumab

## Key facts

- **NCT ID:** NCT03921411
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2020-08-19
- **Final completion:** 2020-08-19
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03921411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03921411, "A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03921411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*